AIM Biotech

AIM Biotech develops and commercializes humanized in vitro physiological models—specifically 3D microfluidic "organ-on-a-chip" systems—for drug discovery and preclinical research. Their platforms enable more predictive data than traditional animal models by recapitulating human tissue complexity. The company also offers contract research services using these systems for applications such as cancer biology, immuno-oncology assays, vasculogenesis studies, cell migration analysis, lead optimization screening, ADME/toxicity studies, safety pharmacology assessments, biomarker identification and cohort selection. No clinical results are reported as they do not develop drugs themselves.